RSS   Newsletter   Contact   Advertise with us
Post Online Media

ICON announces executive leadership transition

ICONICON plc, a provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, announced that Steve Cutler will be appointed as chief executive officer.
Article continues below

READ MORE Transition appoints Carl Damiani as president

Dr. Cutler joined ICON in 2011 as President, ICON Clinical Research Services. He was promoted to ICON plc Chief Operating Officer in January 2014 and was appointed to the Board of Directors in November 2015.

Prior to joining ICON, Dr. Cutler was Chief Executive Officer of Kendle.

Prior to Kendle, he held various senior roles in both Quintiles and Sandoz (now Novartis).

Dr. Cutler holds a B.Sc. and a Ph.D from the University of Sydney and a Masters of Business Administration from the University of Birmingham (UK).

Ciaran Murray will transition to the role of Chairman of the Board of Directors.

Both changes are effective as of 1st March 2017.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy